Compare
MoonLake Immunotherapeutics vs BGM Group Ltd. vs Alumis Inc. vs Nkarta, Inc.
| Latest fiscal year | MoonLake Immunotherapeutics MLTX | BGM Group Ltd. BGM | Alumis Inc. ALMS | Nkarta, Inc. NKTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $37.92M | $24.05M | $0 |
| Revenue growth (YoY) | n/a | +51.1% | n/a | n/a |
| Gross margin | n/a | 16.6% | n/a | n/a |
| Operating margin | n/a | -33.2% | n/m | n/a |
| Net margin | n/a | -52.6% | n/m | n/a |
| Net income | -$227.32M | -$19.94M | -$243.32M | -$104.08M |
| EPS (Diluted) | -$3.53 | -$0.18 | -$2.86 | -$1.41 |
| Operating cash flow | -$196.01M | -$2.37M | -$369.52M | -$88.70M |
| Free cash flow | -$196.04M | -$3.94M | -$370.18M | -$89.91M |
| Cash & equivalents | $334.52M | $9.82M | $89.67M | $39.63M |
| Total assets | $424.43M | $433.81M | $411.94M | $404.21M |
| Total liabilities | $119.95M | $41.92M | $110.64M | $91.88M |
| Shareholders' equity | $304.48M | $391.90M | $301.30M | $312.32M |
| Return on year-end equity | -74.7% | -5.1% | -80.8% | -33.3% |
| Shares outstanding | n/a | 200.62M | n/a | 71.08M |
Revenue, most recent five fiscal years
| Fiscal year | MoonLake Immunotherapeutics | BGM Group Ltd. | Alumis Inc. | Nkarta, Inc. |
|---|---|---|---|---|
| Latest | n/a | $37.92M Ended 2025-09-30 | $24.05M Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $25.10M Ended 2024-09-30 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $46.47M Ended 2023-09-30 | n/a | n/a |
| 3 years earlier | n/a | $64.86M Ended 2022-09-30 | n/a | n/a |
| 4 years earlier | n/a | $57.10M Ended 2021-09-30 | n/a | n/a |